๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Antitumor activity of interleukin 12 in preclinical models

โœ Scribed by M. J. Brunda; Leopoldo Luistro; Leonid Rumennik; Rosemary B. Wright; Mark Dvorozniak; Anthony Aglione; Jon M. Wigginton; Robert H. Wiltrout; Jill A. Hendrzak; Alicia V. Palleroni

Publisher
Springer
Year
1996
Tongue
English
Weight
125 KB
Volume
38
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Imatinib mesylate potentiates topotecan
Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models
โœ Heather P. McDowell; Daniela Meco; Anna Riccardi; Barbara Tanno; Anna C. Berardi ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 331 KB

## Abstract High levels of PDGFR expression in primary rhabdomyosarcoma (RMS) have been associated with disease progression. To date however, there are no reports on the activity of imatinib mesylate, a selective PDGFR inhibitor, in RMS preclinical models. A panel of 5 RMS cell lines was used to in

Preclinical antitumor activity of batrac
Preclinical antitumor activity of batracylin (NSC 320846)
โœ Jacqueline Plowman; Kenneth D. Paull; Ghanem Atassi; Steadman D. Harrison; Donal ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› Springer US ๐ŸŒ English โš– 471 KB

Batracylin (NSC 320846, BAY H 2049), given ip on days 2 and 9 at a dose of 400 mg/kg, inhibited tumor growth completely in 80-100~ of mice with early-stage colon adenocarcinoma 38. Therapeutic efficacy against this subcutaneously implanted tumor was retained upon oral administration of Batracylin al